Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

34.46 +1.21 (+3.64%)
Streaming Delayed Price Updated: 1:58 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Vera Therapeutics to Participate at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024 ↗
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market ↗
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs. 
Via Benzinga
Topics Economy
News headline image
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker ↗
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
News headline image
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 ↗
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Could This Stock Be the Next Biotech Buyout? ↗
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
News headline image
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
News headline image
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
News headline image
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket ↗
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
News headline image
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 ↗
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.